Clinical Development Contract Manufacturing Hormones Research 
Pharmaceutical Technology
FEBRUARY 24, 2023
(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). The company also offers contract manufacturing and laboratory services. It operates in New Zealand, Fiji and the US.
Pharmaceutical Technology
FEBRUARY 24, 2023
(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). The company also offers contract manufacturing and laboratory services. It operates in New Zealand, Fiji and the US.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
JANUARY 23, 2024
Rare diseases, often overlooked in the broader medical research field, affect a small percentage of the population yet carry a significant burden for those diagnosed and their families. Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development.
Pharmaceutical Technology
NOVEMBER 30, 2022
However, there has recently been a boom in interest and research in anti-obesity therapeutics. We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. million in Q3. weight loss in obese or overweight individuals.
Pharmaceutical Technology
NOVEMBER 30, 2022
However, there has recently been a boom in interest and research in anti-obesity therapeutics. We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. million in Q3. weight loss in obese or overweight individuals.
Expert insights. Personalized for you.
100 
Let's personalize your content